Stockwatch: Humans – the weak link in drug development
This article was originally published in Scrip
Executive Summary
The announcement on 4 September that Gilead Sciences, after consultation with the FDA, will be dropping its experimental anti-hepatitis C virus (HCV) compound GS 9190 (tegobuvir) from ongoing clinical trials after two serious adverse events, will cast doubts on this potentially hot target in the treatment of HCV infections (scripintelligence.com, 5 September 2011).